Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Retained Earnings (2016 - 2025)

Historic Retained Earnings for OptimizeRx (OPRX) over the last 17 years, with Q3 2025 value amounting to -$84.3 million.

  • OptimizeRx's Retained Earnings rose 4.03% to -$84.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.3 million, marking a year-over-year increase of 4.03%. This contributed to the annual value of -$84.4 million for FY2024, which is 3129.57% down from last year.
  • According to the latest figures from Q3 2025, OptimizeRx's Retained Earnings is -$84.3 million, which was up 4.03% from -$85.0 million recorded in Q2 2025.
  • In the past 5 years, OptimizeRx's Retained Earnings ranged from a high of -$35.3 million in Q4 2021 and a low of -$86.6 million during Q1 2025
  • In the last 5 years, OptimizeRx's Retained Earnings had a median value of -$57.3 million in 2023 and averaged -$59.1 million.
  • Its Retained Earnings has fluctuated over the past 5 years, first surged by 300.57% in 2021, then plummeted by 4021.1% in 2024.
  • OptimizeRx's Retained Earnings (Quarter) stood at -$35.3 million in 2021, then crashed by 32.45% to -$46.7 million in 2022, then crashed by 37.62% to -$64.3 million in 2023, then crashed by 31.3% to -$84.4 million in 2024, then increased by 0.13% to -$84.3 million in 2025.
  • Its last three reported values are -$84.3 million in Q3 2025, -$85.0 million for Q2 2025, and -$86.6 million during Q1 2025.